Sinotrans Biotechnology responds to stock price flash crash: everything is normal with the company and the progress of products under review.

On January 16th, Jinshi Data reported that the Hong Kong stock market's Xinda Biology (01801.HK) experienced a flash crash, with the stock price falling by more than 14% at one point. Regarding the above dynamics, Xinda Biology stated to reporters that the company's stock price and trading volume had abnormal fluctuations in the afternoon, but the company's business operations are normal and there have been no changes; Currently, the company's products under review, such as Mastinib, Tuzumab, and Pikangqibai, are progressing smoothly and have not changed.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments